Global and China Hemodialysis Market Report

The new patients mainly come from Salsa Pacific region (excluding Japan), whereas for Europe, America, Japan and other mature markets, since these countries eave a higher proportion of patients with advanced renal failure receiving treatment, so they have a slower growth in the number of patients receiving dialysis. For example, in 2013, the number of patients receiving dialysis In Asia-Pacific region grew by 17. 0% YOU; while In Japan, E and US, the number of patients receiving dialysis grew by only 2%-4% YOU.

The global hemophilia’s market can be divided Into two parts: hemophilia’s service and hemophilia’s equipment, of which the scale of hemophilia’s service market Is larger, accounting for about 85% of the overall market. Complete report is available @ http://www. chinamarketresearchreports. Com/114799. HTML . 1 Hemophilia’s Service Market Global hemophilia’s service market has great regional differences: in Europe and Asia Pacific, public institutions dominate, however, in North America, private- company-operated Institutions and In Latin America, private clinics are the mall forms.

Currently, global companies providing hemophilia’s service mainly include Fresheners Medical Care, Davit, etc. The number of patients receiving hemophilia’s in these two companies in 2013 came to nearly 340,000. Dialysis services in China are mainly provided by all levels of hospitals, mainly due to that currently the national health Insurance reimbursement ratio Is relatively low and the affordability of patients is not high, resulting in lower proportion of patients with end-stage renal disease undergoing dialysis treatment, which was only about 12% in 2013.

In 2013 the number of Chinese patients with renal failure undergoing dialysis treatment (mainly hemophilia’s treatment) was approximately 250,000, and number of patients undergoing peritoneal dialysis was less than 30,000. But with the gradual expansion of China’s health insurance coverage at all levels, the proportion of patients with end stage renal disease undergoing treatment will rise sharply and the market prospects will be very promising.